NASDAQ · Biotechnology

RNXT (RNXT) Stock

$0.96 +1.82% NASDAQ: RNXT Healthcare

Valuation

MetricValue
Price$0.96
Market Cap$35.67M
P/E Ratio-2.53
P/B Ratio6.03
P/S Ratio22.04
EPS (TTM)$-0.32
52-Week High$1.45
52-Week Low$0.70
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-220.00%
ROA-137.50%
ROCE-260.00%
Gross Margin-1300.00%
Operating Margin-1300.00%
Net Margin-8.24%
Debt/Equity0.01
Current Ratio4.00

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$1.0M
Operating Profit$-6.0M$-10.0M$-11.0M$-11.0M$-13.0M
Net Profit$-6.0M$-10.0M$-10.0M$-9.0M$-11.0M
EPS$-0.40$-0.54$-0.50$-0.37$-0.32
Op Margin———-25511.6%-1114.0%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$16.0M$7.0M$1.0M$8.0M$8.0M
Total Liabilities$1.0M$1.0M$4.0M$4.0M$3.0M
Cash$15.0M$4.0M$1.0M$7.0M$7.0M
Borrowings$0$0$0$0$0

Latest News

iAccess Alpha Virtual Best Ideas Summer Investment Conference Begins Today ACCESS Newswire · Jun 23, 2026 iAccess Alpha's Virtual Best Ideas Summer Investment Conference June 23–24, 2026 ACCESS Newswire · Jun 18, 2026 RenovoRx Highlights Peer-Reviewed Publication Supporting Intra-Arterial Gemcitabine Delivery Via TAMP™ in Locally Advanced Pancreatic Cancer GlobeNewswire · Jun 11, 2026 RenovoRx CEO, Shaun Bagai, to Present at the iAccess Alpha Virtual Best Ideas Summer Investment Conference 2026 on June 23rd GlobeNewswire · Jun 4, 2026 RenovoRx Announces FDA Orphan Drug Designation Granted: Oxaliplatin for the Treatment of Pancreatic Cancer GlobeNewswire · May 28, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-6.0M$-9.0M$-10.0M$-9.0M$-11.0M
Investing Cash Flow$0$-2.0M$2.0M$0$0
Financing Cash Flow$3.0M$0$0$0$-1.0M
Net Cash Flow$13.0M$-11.0M$-3.0M$6.0M$0
Free Cash Flow$-6.0M$-9.0M$-10.0M$-9.0M$-11.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-34.44%
Quick Ratio6.95
Interest Coverage—
Return 1Y-34.09%
Return 3Y-59.53%
Return 5Y—

Ownership

Insiders Held3.42%
Institutions Held18.96%
Institutions Float Held19.64%
Institutional HolderSharesReport Date
AIGH Capital Management LLC3,706,1972026-03-31
Bleichroeder LP1,666,0982026-03-31
Vanguard Capital Management LLC1,447,1772026-03-31
Geode Capital Management, LLC381,7232026-03-31
Wealthspire Advisors, LLC252,5252026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ANVS $1.70 +0.59% -1.54 $33.45M 0.00%
BCABBioAtla, Inc. $3.40 +0.89% -0.08 $4.29M 0.00%
CALCCalciMedica, Inc. $0.73 -3.82% -0.57 $11.55M 0.00%
CELUCelularity Inc. $0.75 +0.13% -0.20 $21.74M 0.00%
ELUT $0.86 -5.33% -1.24 $37.88M 0.00%

About RNXT

RNXT is led by CEO Shaun R. Bagai, employs 10 people, headquartered in US, publicly traded since 2021.

RNXT stock trades at $0.96 with a market capitalization of $35.67M. The stock is valued at a price-to-earnings (P/E) ratio of -2.53, price-to-book of 6.03, price-to-sales of 22.04. Over the past 52 weeks the stock has ranged between $0.70 and $1.45, and currently trades 33.8% below its 52-week high.

On profitability, RNXT generates a return on equity (ROE) of -220.00%, return on capital employed of -260.00%, an operating margin of -1300.00%, a net profit margin of -8.24%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides